BRIEF-Lundbeck and Otsuka expand collaboration on schizophrenia drug

COPENHAGEN, March 7 Thu Mar 7, 2013 1:10am EST

Related Topics

COPENHAGEN, March 7 (Reuters) - Lundbeck A/S : * Says Otsuka and Lundbeck expand their existing collaboration * Says collaboration to include promotion of Abilify swallowable tablets, oral

solution, orally-disintegrating tablets and the intramuscular rapid

injectable in 14 European countries. * A once-monthly injectable form of Abilify, will be co-promoted by Otsuka and Lundbeck in the U.S. and will start becoming available there from March 18. * The drug was approved for use in schizophrenia by the U.S. FDA (Food and Drug Administration) on February 28.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.